Page 117 - 202012
P. 117

杂志,2009,32(8):634-636.                             Acad Dermatol,2015,72(2):314-320.
        [ 2 ]  CAO C,XI L,CHATURVEDI V. Talaromycosis(penicilli-  [15]  BOAST A,CURTIS N,CRANSWICK N,et al. Voricon-
             osis)due to talaromyces(penicillium)marneffei:insights  azole dosing and therapeutic drug monitoring in children:
             into the clinical trends of a major fungal disease 60 years  experience from a paediatric tertiary care centre[J]. J Anti-
             after the discovery of the pathogen[J]. Mycopathologia,  microb Chemother,2016,71(7):2031-2036.
             2019,184(6):709-720.                          [16]  JOHNSON LB,KAUFFMAN CA. Voriconazole:a new
        [ 3 ]  WONGKAMHLA T,CHONGTRAKOOL P,JITMUANG             triazole antifungal agent[J]. Clin Infect Dis,2003,36(5):
             A. A case report of talaromyces marneffei oropharyngo-  630-637.
             laryngitis:a rare manifestation of Talaromycosis[J].BMC  [17] 《中国国家处方集》编委会.中国国家处方集:化学药品与
             Infect Dis,2019. DOI:10.1186/s12879-019-4650-7.    生物制品卷:儿童版[M].北京:人民军医出版社,2013:
        [ 4 ]  LEE PP,CHAN KW,LEE TL,et al. Penicilliosis in chil-  443-444.
             dren without HIV infection-are they immunodefificient?[J].  [18]  ZIMMERMANN T,YEATES RA,LAUFEN H,et al. In-
             Clin Infect Dis,2012,54(2):e8-e19.                 fluence of concomitant food intake on the oral absorption
        [ 5 ]  何礼贤,肖永红,陆权,等.中国国家抗微生物治疗指                         of two triazole antifungal agents,itraconazole and flucon-
             南[M].2版.北京:人民卫生出版社,2018:23.                        azole[J]. Eur J Clin Pharmacol,1994,46(2):147-150.
        [ 6 ]  ZENG W,QIU Y,LU D,et al. A retrospective analysis of  [19]  孙黎,刘晓琰,费艳秋.伊曲康唑制剂的临床应用[J].医药
             7 human immunodefificiency virus negative infants in-  导报,2002,21(2):99-101.
             fected by Penicillium marneffei[J]. Medicine:Baltimore,  [20]  ALLEGRA S,FATIGUSO G,DE FRANCIA S,et al. Phar-
             2015. DOI:10.1097/MD.0000000000001439.             macokinetic evaluation of oral itraconazole for antifungal
        [ 7 ]  OUYANG Y,CAI S,LIANG H,et al.Administration of   prophylaxis in children[J]. Clin Exp Pharmacol Physiol,
             voriconazole in disseminated Talaromyces(penicillium)  2017,44(11):1083-1088.
             marneffei infection:a retrospective study[J]. Mycopatholo-  [21]  LYDIA L. BENITEZ,PEGGY L. Carver. Adverse efects
             gia,2017,182(5/6):569-575.                         associated with long term administration of azole antifun-
        [ 8 ]  ASHBEE HR,BARNES RA,JOHNSON EM,et al. Thera-     gal agents[J]. Drugs,2019,79(8):833-853.
             peutic drug monitoring(TDM)of antifungal agents:guide-  [22]  BARONE JA,MOSKOVITZ BL,GUARNIERI J,et al.
             lines from the British Society for Medical Mycology[J]. J  Enhanced bioavailability of itraconazole in hydroxypro-
             Antimicrob Chemother,2014,69(5):1162-1176.         pyl-β-cyclodextrin solution versus capsules in healthy vol-
        [ 9 ]  中国医药教育协会感染疾病专业委员会.抗菌药物药代                         unteers[J]. Antimicrob Agents Chemother,1998,42(7):
             动力学药效学理论临床应用指导原则[J].中华结核和呼                         1862-1865.
             吸杂志,2018,41(6):409-446.                       [23]  WINSTON DJ,MAZIARZ RT,CHANDRASEKAR PH,
        [10]  LE T,LY VT,THU NTM,et al. Population pharmacody-  et al. Intravenous and oral itraconazole versus intravenous
             namics of amphotericin B deoxycholate for disseminated  and oral fluconazole for long-term antifungal prophylaxis
             infection caused by Talaromyces marneffei[J]. Antimicrob  in allogeneic hematopoietic stem-cell transplant recipi-
             Agents Chemother,2019. DOI:10.1128/AAC.01739-18.   ents. a multicenter,randomized trial[J]. Ann Intern Med,
        [11]  钟活麟,陈谐捷,张坚生,等.儿童艾滋病合并马尔尼菲青                        2003,138(9):705-713.
             霉病 30 例临床资料分析[J].中国医药指南,2013,33               [24]  WANG P,WANG X,YANG X,et al. Budesonide sup-
            (11):36-37.                                         presses pulmonary antibacterial host defense by down-reg-
        [12]  CROSS LJ,BAGG J,AITCHISON TC. Efficacy of the cy-  ulating cathelicidin-related antimicrobial peptide in aller-
             clodextrin liquid preparation of itracona-zole in treatment  gic inflammation mice and in lung epithelial cells[J].
             of denture stomatitis:comparison with itraconazole cap-  BMC Immunology,2013. DOI:10.1186/1471-2172-14-7.
             sules[J]. Antimicrob Agents Chemother,2000,44(2):  [25]  SUPPARATPINYO K,SIRISANTHANA T. Diagnosis
             425-427.                                           and treatment of marneffei infection.(2019-08-27)[2019-
        [13]  张馨予,陈集敏,梁伶,等.几种抗真菌药物对马尔尼菲青                        11-20]. https://www.uptodate.com/contents/zh-Hans/diag-
             霉的体外药敏试验[J].中华皮肤科杂志,2012,45(4):                    nosis-and-treatment-of-talaromyces-penicillium-marnef-
             234-237.                                           fei-infection?
        [14]  SHEU J,HAWRYLUK EB,GUO D,et al. Voriconazole              (收稿日期:2020-03-13   修回日期:2020-05-07)
             phototoxicity in children:a retrospective review[J]. J Am                          (编辑:陈 宏)




        中国药房    2020年第31卷第12期                                            China Pharmacy 2020 Vol. 31 No. 12  ·1515  ·
   112   113   114   115   116   117   118   119   120   121   122